Skip to content

Eli Lilly

Recent events

Recent events tied to this brand in public sources.

Back to profile61 entries · Page 2 of 4

  1. 2023

    Eli Lilly sues clinics over alleged unauthorized Mounjaro versions

    Eli Lilly sued 10 medical spas, wellness clinics and compounding pharmacies across the U.S., alleging that they marketed and sold cheaper, unauthorized versions of its Mounjaro drug. The suits sought orders blocking sales and monetary damages; the allegations are claims in litigation.

  2. 2023

    Nektar sues Eli Lilly over rezpegaldesleukin collaboration

    Nektar Therapeutics sued Eli Lilly, accusing the company of undermining prospects for rezpegaldesleukin, a drug they had been developing together. The complaint alleges breach of contract, negligent misrepresentation, unfair competition and other wrongdoing; the allegations are not presented as court findings.

  3. 2023

    Eli Lilly and Novo Nordisk sued over alleged stomach paralysis risks

    A personal injury firm filed suit against Eli Lilly and Novo Nordisk on behalf of a Louisiana woman, alleging that the companies failed to warn consumers about gastroparesis risks associated with Mounjaro and Ozempic. The allegations are not presented as a court finding.

  4. 2023

    Lawsuit filed against makers of Ozempic and Mounjaro

    A Louisiana woman filed a lawsuit alleging that Novo Nordisk and Eli Lilly failed to adequately warn patients about possible severe stomach problems associated with Ozempic and Mounjaro. The allegations have not been determined in the supplied evidence.

  5. 2023

    Cleveland sues insulin companies over alleged pricing scheme

    The city of Cleveland sued drug makers, pharmacy benefit managers, and corporate conglomerates, alleging a conspiracy to overcharge the city for insulin. Named companies include Eli Lilly, Express Scripts, and CVS; the claims are allegations, and CVS Health rejects the claims against it.

  6. 2023

    Eli Lilly to acquire remaining Sigilon shares

    Eli Lilly announced that it would acquire the Sigilon Therapeutics shares it does not already own for $14.92 per share, or $34.6 million in cash. The deal was expected to close in the third quarter of 2023.

  7. 2023

    Eli Lilly agrees to acquire Dice

    Eli Lilly announced that it had agreed to buy Dice, a biotechnology firm specializing in oral treatments for autoimmune diseases, for $2.4 billion.

  8. 2023

    Nido Biosciences raises $109 million

    Nido Biosciences emerged from stealth with $109 million in combined seed, Series A, and Series B funding. Eli Lilly participated in the Series A round.

  9. 2023

    Roche and Lilly partner on Alzheimer’s blood-test validation

    Roche and Eli Lilly announced a collaboration to validate an Alzheimer’s blood test, with plans for a two-year clinical trial involving hundreds of volunteers.

  10. 2023

    Eli Lilly expands its $35 monthly insulin cost cap

    Eli Lilly announced an expansion of its program capping patient insulin costs at $35 per month. The company said privately insured patients would receive the cap and uninsured people could enroll in a program to receive it.

  11. 2023

    Eli Lilly announces planned insulin price cuts

    Eli Lilly announced that it plans to cut the list prices of Humalog and Humulin by 70% in the fourth quarter, and to reduce the price of its authorized generic Humalog to $25 per vial starting in May.

  12. 2023

    FDA approves Eli Lilly's Jaypirca for a rare blood cancer

    The U.S. Food and Drug Administration approved Eli Lilly's drug Jaypirca for treatment of a rare form of blood cancer.

  13. 2023

    FDA grants accelerated approval for Jaypirca

    The FDA granted accelerated approval to pirtobrutinib (Jaypirca) for certain adults with advanced mantle cell lymphoma who have received at least two prior lines of systemic therapy, including a BTK inhibitor.

  14. 2022

    FDA approves REZVOGLAR as interchangeable biosimilar

    The FDA approved Eli Lilly's REZVOGLAR as the second interchangeable biosimilar to LANTUS.

  15. 2022

    Boryung acquires Korean selling rights to Alimta

    Boryung acquired the local selling rights to Eli Lilly’s Alimta in South Korea. The article notes that completion of the rights transaction remains subject to regulatory reviews and closing conditions.

  16. 2022

    FDA approves Olumiant for alopecia areata

    The U.S. Food and Drug Administration approved Eli Lilly's Olumiant as a treatment for alopecia areata, the first treatment approved for the condition.

  17. 2022

    Whistleblower sues Eli Lilly over manufacturing practices

    Former Eli Lilly human resources officer Amrit Mula sued the company, alleging she was terminated after raising concerns about poor manufacturing practices and data falsification involving its diabetes drug. The allegations are not presented as a court determination.

  18. 2022

    Arkansas sues insulin manufacturers over prices

    Arkansas Attorney General Leslie Rutledge announced a lawsuit against Eli Lilly, Novo Nordisk and Sanofi, alleging they helped drive up insulin prices in the state.

  19. 2022

    Eli Lilly announces an approximately $700 million facility investment

    Eli Lilly revealed plans for an investment of around $700 million to establish a facility at its new site in Boston, as part of its plan to advance RNA-based treatments.

  20. 2021

    Eli Lilly announces a planned 40% insulin price reduction

    Eli Lilly announced that it would lower the price of the insulin it produces by 40%, starting January 1, 2022. The article reports an announced future price change, not that the reduction had already taken effect.